Grace Therapeutics rises after late‑stage win for brain bleeding drug

Grace Therapeutics

14/04/2026 13:22

** Shares of biotech firm Grace Therapeutics GRCE.O rise 3.5% to $3.95 premarket

** Co says its experimental injectable drug GTx‑104 met its main goal in a late‑stage trial for aneurysmal subarachnoid hemorrhage, a rare type of stroke caused by bleeding on the surface of the brain

** Says trial showed a 19% lower rate of dangerous low blood pressure versus standard oral nimodipine, the current treatment

** Says more patients on GTx‑104 were able to receive higher doses and had better recovery outcomes after 90 days

** Says side effects were similar between groups, with no new safety concerns identified

** Says it plans to seek regulatory approval and will present full data at a neurology conference later this month

** As of last close, stock up ~8% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))